Citius Pharmaceuticals Inc. (NASDAQ: CTXR)
$0.1265
-0.0386 ( -5.60% ) 12.7M
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Market Data
Open
$0.1265
Previous close
$0.1651
Volume
12.7M
Market cap
$24.17M
Day range
$0.1100 - $0.1680
52 week range
$0.1100 - $1.0700
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jan 23, 2024 |
8-k | 8K-related | 12 | Jan 05, 2024 |
8-k | 8K-related | 16 | Jan 02, 2024 |
10-k | Annual reports | 64 | Dec 29, 2023 |